For vaccination against hepatitis A and/or hepatitis B…

GSK offers multiple immunization options for your adult patients

TWINRIX®
Hepatitis A & Hepatitis B (Recombinant) Vaccine
720 EL.U./mL of inactivated hepatitis A virus
20 mcg/mL of recombinant hepatitis B surface antigen protein

For vaccination of adults (≥18 years of age) against hepatitis A and hepatitis B[1]

Standard Dosing
A series of 3 doses given at 0, 1, and 6 months

Accelerated Dosing
A series of 3 doses given on days 0, 7, and 21-30, followed by a booster dose at month 12

Havrix®
Hepatitis A Vaccine
1440 EL.U./mL of inactivated hepatitis A virus

For vaccination of adults (≥19 years of age) against hepatitis A[2]



1 dose given at 0 months, followed by a booster dose given between 6 and 12 months later

Engerix-B®
Hepatitis B Vaccine (Recombinant)
20 mcg/mL of recombinant hepatitis B surface antigen protein

For vaccination of adults (≥20 years of age) against hepatitis B[3]

A series of 3 doses given at 0, 1, and 6 months

There are alternate dosing schedules. Please see full Prescribing Information for ENGERIX-B.

Important Safety Information for TWINRIX, HAVRIX, and ENGERIX-B

- Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis A-containing or hepatitis B-containing vaccine, or to any component of TWINRIX, including yeast and neomycin, is a contraindication to administration of TWINRIX
- Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis A-containing vaccine, or to any component of HAVRIX, including neomycin, is a contraindication to administration of HAVRIX
- Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B-containing vaccine, or to any component of ENGERIX-B, including yeast, is a contraindication to administration of ENGERIX-B

Indication for TWINRIX

TWINRIX is a vaccine indicated for active immunization against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus. TWINRIX is approved for use in persons 18 years of age or older.

Indication for HAVRIX

HAVRIX is a vaccine indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.

Indication for ENGERIX-B

ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus.

Please see additional Important Safety Information for TWINRIX, HAVRIX, and ENGERIX-B on page 2.

Please see accompanying full Prescribing Information for TWINRIX, HAVRIX, and ENGERIX-B.

TWINRIX®
Hepatitis A & Hepatitis B (Recombinant) Vaccine

Havrix®
Hepatitis A Vaccine

Engerix-B®
Hepatitis B Vaccine (Recombinant)

Important Safety Information for TWINRIX, HAVRIX, and ENGERIX-B

- Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis A-containing or hepatitis B-containing vaccine, or to any component of TWINRIX, including yeast and neomycin, is a contraindication to administration of TWINRIX
- Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis A-containing vaccine, or to any component of HAVRIX, including neomycin, is a contraindication to administration of HAVRIX
- Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B-containing vaccine, or to any component of ENGERIX-B, including yeast, is a contraindication to administration of ENGERIX-B
- The tip caps of the prefilled syringes for TWINRIX, HAVRIX, and ENGERIX-B contain natural rubber latex, which may cause allergic reactions
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Temporarily defer ENGERIX-B vaccination of infants with a birth weight less than 2,000 grams born to hepatitis B surface antigen (HBsAg)-negative mothers
- Apnea following intramuscular vaccination with ENGERIX-B has been observed in some infants born prematurely
- Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to TWINRIX, HAVRIX, or ENGERIX-B
- In clinical trials with TWINRIX, the most common solicited injection site reactions were injection site soreness and redness; the most common solicited systemic adverse reactions were headache and fatigue
- In clinical trials with HAVRIX in children 11 to 25 months of age, the most common solicited adverse reactions were injection-site pain and redness, irritability, drowsiness, and loss of appetite
- In clinical trials with HAVRIX in adults and children 2 years of age and older, the most common solicited adverse reactions were injection-site soreness and headache
- In clinical trials with ENGERIX-B, the most frequently reported adverse reactions were injection-site soreness and fatigue
- Vaccination with TWINRIX, HAVRIX, or ENGERIX-B may not result in protection in all vaccine recipients

References: 1. Prescribing Information for TWINRIX. **2.** Prescribing Information for HAVRIX. **3.** Prescribing Information for ENGERIX-B.

TWINRIX®
Hepatitis A & Hepatitis B (Recombinant) Vaccine

Havrix®
Hepatitis A Vaccine

Engerix-B®
Hepatitis B Vaccine (Recombinant)

www.GSKSource.com

MLVLBND190006 February 2019
Produced in USA. 0002-0000-53